Samsung Biologics Co., Ltd.

Samsung Biologics is a global contract development and manufacturing organization (CDMO) headquartered in Songdo, Incheon, South Korea. The company's mission, encapsulated by "Driven. For Life.", is to serve as a trusted partner to its clients, working collaboratively to advance biomedicines for the betterment of human health.

As a fully integrated CDMO, Samsung Biologics offers end-to-end services encompassing biologics development, cGMP manufacturing, and aseptic fill/finish. Its comprehensive offerings include cell line development, process development, analytical development, and the manufacturing of drug substances and drug products. The company specializes in a range of modalities, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), mRNA vaccines, recombinant proteins, and Fc fusion proteins, serving biopharmaceutical partners globally from late discovery through large-scale commercial production.

Led by President and CEO John Rim, Samsung Biologics maintains its position as a leader in biomanufacturing with the world's largest capacity, which includes its facilities in Songdo, South Korea, and a recently acquired manufacturing site in Rockville, Maryland, USA. In November 2025, the company completed the spin-off of its biosimilar division, Samsung Bioepis, into a new holding company, Samsung Epis Holdings, solidifying Samsung Biologics' focus as a pure-play CDMO. As of May 2026, the company has been navigating a labor dispute involving a strike by unionized workers seeking wage increases and greater involvement in corporate decisions.